Carcinoma, Pancreatic Ductal Clinical Trial
Official title:
Impact of Nationwide Enhanced Implementation of Best Practices in Pancreatic Cancer Care (PACAP-1): a Multicenter Stepped-wedge Cluster Randomized Controlled Trial
PACAP-1 will evaluate to what extent an enhanced implementation of best practices in pancreatic cancer care leads to a prolonged survival and improvement of quality of life as compared to current practice.
Rationale: The Dutch Pancreatic Cancer Project (PACAP) is an initiative of the Dutch Pancreatic Cancer Group and was officially launched in July 2014. PACAP is 1 of the largest nationwide collaborative outcomes registration and biobanking projects on pancreatic and periampullary cancer worldwide and includes the Dutch Pancreatic Cancer Audit (DPCA), the Patient Reported Outcome Measures (PROMs), an online expert panel, and the Netherlands Cancer Registry (NCR, Netherlands Comprehensive Cancer Organization; IKNL). During the first 3 years of PACAP, regional variations in treatment and guideline (non-)compliance were observed. These differences may lead to differences in survival and quality of life of pancreatic cancer patients throughout the Netherlands. From PACAP data and literature, best practices for pancreatic cancer care have been identified. Objective: The aim of PACAP-1 is to evaluate to what extent an enhanced implementation of best practices in pancreatic cancer care in the Netherlands leads to a prolonged survival and improvement of quality of life as compared to current practice. Study design: The PACAP-1 trial is a nationwide stepped-wedge cluster randomized controlled trial. In a per center stepwise and randomized manner, best practices in pancreatic cancer care are implemented in all 17 Dutch pancreatic centers. A regional pancreatic cancer team will be established per pancreatic center that functions as point of contact for peripheral centers in the region. Patient outcomes and compliance will be monitored by the registries founded in the PACAP initiative. Study Population: Prospective cohort of all pancreatic cancer patients diagnosed and treated in the Netherlands. Interventions: Best practices will be implemented in 3 key medical specialties in pancreatic cancer care: medical oncology, surgery and gastroenterology. Best practices will be implemented in centers during a 6 week intensive initiation period which includes monitoring, return visits, provider feedback in combination with education and reminders. The best practices follow the Dutch guideline on pancreatic cancer and the current state of the literature and can be executed without additional overall costs per center. Main study outcomes: The primary outcome is 1-year overall survival. Secondary outcomes include quality of life (first secondary outcome), 3- and 5-year overall survival and success of implementation of every PACAP-1 intervention and participation in DPCG randomized trials. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03500068 -
Establishing Organoids From Metastatic Pancreatic Cancer Patients, the OPT-I Study.
|
N/A | |
| Not yet recruiting |
NCT05489458 -
Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy
|
||
| Recruiting |
NCT02310230 -
An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy
|
N/A | |
| Completed |
NCT01478685 -
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT01808638 -
Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT00226746 -
Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT03432624 -
Detection of MicroRNA-25 in the Diagnosis of Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT02529579 -
Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02451384 -
According CTC to Compare the Influences of Different Methods to Remove the PDAC
|
N/A | |
| Not yet recruiting |
NCT06447662 -
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
|
Phase 1 | |
| Recruiting |
NCT02817308 -
Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas
|
N/A | |
| Completed |
NCT00471146 -
Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.
|
Phase 3 | |
| Recruiting |
NCT05461430 -
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
|
||
| Terminated |
NCT01413451 -
Amatuximab for High Mesothelin Cancers
|
Early Phase 1 | |
| Recruiting |
NCT03403101 -
The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT02928081 -
Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy for Patients With Pancreatic Head Adenocarcinoma
|
N/A | |
| Completed |
NCT05723978 -
Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.
|
||
| Completed |
NCT02150746 -
Circulating Tumor Cells in Operative Blood
|
N/A | |
| Completed |
NCT04146441 -
Ultrasound-enhanced Uptake of Chemotherapy in Patients With Inoperable Pancreatic Ductal Adenocarcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT05621824 -
A Cohort Study on Screening and Follow-up of High-risk Population of PDAC Based on EUS
|